Editorial Podcasts

Christine McSherry, CEO of Casimir and Mindy Leffler, President and Chairman of Casimir, now a part of CRO Emmes, discuss their path to true patient focused drug development based on their experiences raising sons with Duchenne Muscular Dystrophy (DMD). By understanding early and actual measurable endpoints that matter to DMD patients and caregivers, and providing PROs that can capture data that matters, the women hope to influence other diseases and the quality of life for people that have very little time to waste.

Dr. Ian Smith MBE MB ChB.B MedSc(Hons), Founder, Director and Chief Medical Officer of Panthera Biopartners, and Chris Dodd, the company's Chief Commercial Officer, discuss the evolution of the Site Management Organization and Panthera Biopartners, how clinical trials remain mired in underperformance and difficulties, and hybrid trial advancements.

Praduman “PJ” Jain, CEO & Founder, Vibrent Health; Principal Investigator, NIH All of Us Research Program, Participant Technology Systems Center; Principal Investigator, NIH RADx Program, discusses his involvement in the NIH All of Us program, digital health research tools, and more.

Judy Canavan, Managing Director and Leader at BDO, Compensation and Benefits practice, discusses how BDO collects the data for its CRO Industry Global Compensation & Turnover Survey, recent calls for CROs to invest in their HR departments, and the effect of the Great Resignation on the industry.

Jenny Ahlstrom, founder of the HealthTree Foundation, discusses their community for AML and myeloma patients, how they help their patients navigate clinical trials, how their portal seamlessly gets patients records to researchers, and how industry can utilize their resources and engage with patients.

Brad Power, Founder of CancerHacker Lab, speaks about his innovative crowdsourcing approach to help cancer patients, his own battle with lymphoma, and the unique challenges brought to the table by clinical trials in oncology.

Mike Rea, CEO and Founder of IDEA Pharma, speaks about how his newly launched sister company—Protodigm—takes lessons learned from IDEA, combined with ideas borrowed from engineering and tech development, to form a new concept in pharma and biotech to innovate drug development with minimized risk and without bias.